10.16
-0.10 (-0.97%)
| Previous Close | 10.26 |
| Open | 10.21 |
| Volume | 1,820,831 |
| Avg. Volume (3M) | 1,299,125 |
| Market Cap | 735,333,568 |
| Price / Earnings (TTM) | 8.91 |
| Price / Earnings (Forward) | 58.14 |
| Price / Sales | 80.03 |
| Price / Book | 8.44 |
| 52 Weeks Range | |
| Earnings Date | 13 Aug 2026 |
| Diluted EPS (TTM) | -3.04 |
| Current Ratio (MRQ) | 1.16 |
| Operating Cash Flow (TTM) | -142.86 M |
| Levered Free Cash Flow (TTM) | -102.50 M |
| Return on Assets (TTM) | -30.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Omeros Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.90 |
|
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.40% |
| % Held by Institutions | 47.30% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Stifel Financial Corp | 31 Mar 2026 | 1,831,585 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CABLE THOMAS J. | - | 11.46 | -7,500 | -85,950 |
| Aggregate Net Quantity | -7,500 | |||
| Aggregate Net Value ($) | -85,950 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 11.46 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CABLE THOMAS J. | Director | 22 May 2026 | Automatic sell (-) | 7,500 | 11.46 | 85,950 |
| CABLE THOMAS J. | Director | 22 May 2026 | Option execute | 7,500 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |